Research Advances in the Treatment of Eltrombopag for Adult Patients with Primary Immune Thrombocytopenia——Review
10.19746/j.cnki.issn1009-2137.2024.05.050
- VernacularTitle:艾曲泊帕治疗成人原发免疫性血小板减少症的最新研究进展
- Author:
Mu-Chen XIE
1
;
Zhi-Qiang SUN
;
Yan-Bin PANG
Author Information
1. 南方医科大学深圳医院血液内科,广东深圳 518100
- Keywords:
primary immune thrombocytopenia;
immune abnormalities;
eltrombopag;
thrombosis;
bone marrow fibrosis
- From:
Journal of Experimental Hematology
2024;32(5):1622-1625
- CountryChina
- Language:Chinese
-
Abstract:
Primary immune thrombocytopenia(ITP)is an autoimmune disease characterized by thrombocytopenia,and T cell immune dysfunction plays an important role in the formation of ITP.As a thrombopoietin receptor agonist(TPO-RA),eltrombopag can not only directly stimulate megakaryocytes to produce platelets,but also play an immunomodulatory role by inducing regulatory T cell generation and reducing proinflammatory factors.As a second-line treatment drug for adult ITP,eltrombopag is increasingly widely used in clinical practice.This review summarized the latest research progress on the mechanism of action,efficacy,safety,and how to reduce the dosage of eltrombopag in ITP.
